IPO registrations (S-1, F-1) · Registrants
DiaMedica Therapeutics Inc.
- SEC CIK
- 1401040 · filings on EDGAR ↗
- Former names
- DiaMedica Inc. (2007–2014)
- Registration
- Form S-1, first filed 2018-11-09, last 2018-11-28; 1 initial registration, 3 amendments
- Outcome
- Final prospectus filed 2018-12-10; declared effective 2018-12-06
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- Z4
- Business address
- 301 CARLSON PARKWAY, SUITE 210, Minneapolis, MN 55305
- Ticker
- DMAC (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- DiaMedica Therapeutics Inc. on the corporate pages
Offering terms
- Proposed price range
- $4.00–$5.00 per share (S-1/A filed 2018-11-28)
- Final price
- $4.00 per share, within the range (424B4 filed 2018-12-10, an initial public offering)
- Shares sold
- 4,100,000
- Gross proceeds
- $16,400,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol DMAC
- Lead underwriters
- Craig-Hallum
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form D issuer: DiaMedica Therapeutics Inc. EXACT (CIK (EXACT))
- SEC filer: DiaMedica Therapeutics Inc. EXACT (CIK (EXACT))
Filings 7
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2018-11-09 | S-1 | S-1 (registration) | DiaMedica Therapeutics Inc. | 0001437749-18-020300 ↗ |
| 2018-11-19 | S-1/A | S-1/A (amendment) | DiaMedica Therapeutics Inc. | 0001437749-18-021086 ↗ |
| 2018-11-27 | S-1/A | S-1/A (amendment) | DiaMedica Therapeutics Inc. | 0001437749-18-021292 ↗ |
| 2018-11-28 | S-1/A | S-1/A (amendment) | DiaMedica Therapeutics Inc. | 0001437749-18-021321 ↗ |
| 2018-12-06 | EFFECT | EFFECT (declared effective) | DiaMedica Therapeutics Inc. | 9999999995-18-003050 ↗ |
| 2018-12-10 | 424B4 | 424B4 (final prospectus) | DiaMedica Therapeutics Inc. | 0001437749-18-021842 ↗ |
| 2020-01-09 | EFFECT | EFFECT (declared effective) | DiaMedica Therapeutics Inc. | 9999999995-20-000060 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2018-11-28 | S-1/A | registration statement | $4.00–$5.00 | $4.90 | 4,000,000 | $19,600,000 | Nasdaq DMAC | 1 | primary document; range, price sentence, shares headline, proceeds computed | document ↗ |
| 2018-12-10 | 424B4 | final prospectus | $4.00 | 4,100,000 | $16,400,000 | Nasdaq DMAC | 1 | primary document; price sentence, shares headline, proceeds table, cover names 1 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| ALCORN HARRY W JR | Officer | Chief Medical Officer; Senior VP, Clinical Operations; SVP, Clinical Operations | 9 | 2018–2021 | |
| Giuffre Randall Michael | Director | 23 | 2018–2026 | ||
| Hermeda Industrial Co., Ltd | TenPercentOwner | 1 | 2018 | ||
| Kellen Scott | Officer | CFO and Secretary; CFO & Secretary | 15 | 2018–2026 | |
| Parsons James T. | Director | 16 | 2018–2026 | ||
| Pauls Dietrich John | Director,Officer | President and CEO; President & CEO | 15 | 2018–2026 | |
| Pilnik Richard D. | Director | 20 | 2018–2025 | ||
| Verdoorn Todd A. | Officer | Chief Scientific Officer | 3 | 2018–2019 | |
| Xiao Zhenyu | Director; Director,TenPercentOwner | 3 | 2018–2019 | ||
| Gilman Sydney A. | Officer | VP, Regulatory Affairs | 4 | 2019–2021 | |
| Burroughs Amy L. | Director | 6 | 2021–2023 | ||
| Semba Charles Pauling | Director | 12 | 2021–2026 | ||
| Gruis Kirsten L | Officer | Chief Medical Officer | 3 | 2022–2023 | |
| Cundari Dominic R | Officer | Chief Commercial Officer | 4 | 2022–2024 | |
| TomEnterprise AB | TenPercentOwner | 6 | 2022–2025 | ||
| Von Koch Thomas | TenPercentOwner | 6 | 2022–2025 | ||
| Daves Julie VanOrsdel | Officer | SVP Clinical Development Oper. | 3 | 2022–2023 | |
| TomEnterprise Private AB | TenPercentOwner | 4 | 2022–2025 | ||
| Lewis Tanya | Director | 6 | 2023–2026 | ||
| Wambeke David J. | Officer | Chief Business Officer | 6 | 2023–2025 | |
| Kuntz Richard | Director | 7 | 2023–2026 | ||
| JACINTO RICHARD II | TenPercentOwner | 2 | 2023–2025 | ||
| STAHLBERG JAN | TenPercentOwner | 5 | 2023–2025 | ||
| TRILL AB | TenPercentOwner | 5 | 2023–2025 | ||
| Lorianne Masuoka K. | Officer | Chief Medical Officer | 2 | 2024 | |
| O'Connor Daniel J. | Director | 3 | 2025–2026 | ||
| Krop Julie | Officer | Chief Marketing Officer; Chief Medical Officer | 3 | 2025–2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2025-07-25 | DiaMedica Therapeutics Inc. | Biotechnology | $30,100,000 | $30,100,000 | 14 | 1 |
| 2024-07-02 | DiaMedica Therapeutics Inc. | Biotechnology | $11,800,000 | $11,800,000 | 10 | 1 |
| 2023-06-27 | DiaMedica Therapeutics Inc. | Biotechnology | $37,536,853 | $37,536,853 | 34 | 1 |
| 2023-04-18 | DiaMedica Therapeutics Inc. | Biotechnology | $750,000 | $750,000 | 1 | 1 |
| 2021-10-06 | DiaMedica Therapeutics Inc. | Biotechnology | $29,999,995 | $29,999,995 | 10 | 1 |
| 2018-04-17 | DiaMedica Therapeutics Inc. | Biotechnology | $344,348 | $200,870 | 7 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | DiaMedica Therapeutics Inc. | MN | Form D private offerings | CIK (EXACT) |
| SEC filer | DiaMedica Therapeutics Inc. | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, MN first:
- LIFECORE BIOMEDICAL, INC. \DE\ MN
- Panbela Therapeutics, Inc. MN
- Enterologics, Inc. MN
- Vireo Growth Inc. MN
- Squarex Pharmaceutical Corp MN
- Life Science Holdings, Inc. MN
- CIMA LABS INC MN
- MorphoSys AG 2M
- Affimed N.V. 2M
- InflaRx N.V. 2M
In other datasets, the same topic (Health) in MN:
- Nonprofit: ABBOTT NORTHWESTERN HOSPITAL FOUNDATION (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health